JP2005523334A5 - - Google Patents

Download PDF

Info

Publication number
JP2005523334A5
JP2005523334A5 JP2003587377A JP2003587377A JP2005523334A5 JP 2005523334 A5 JP2005523334 A5 JP 2005523334A5 JP 2003587377 A JP2003587377 A JP 2003587377A JP 2003587377 A JP2003587377 A JP 2003587377A JP 2005523334 A5 JP2005523334 A5 JP 2005523334A5
Authority
JP
Japan
Prior art keywords
use according
pharmaceutical compound
disorder
group
stress
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003587377A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005523334A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/013247 external-priority patent/WO2003090743A1/en
Publication of JP2005523334A publication Critical patent/JP2005523334A/ja
Publication of JP2005523334A5 publication Critical patent/JP2005523334A5/ja
Withdrawn legal-status Critical Current

Links

JP2003587377A 2002-04-24 2003-04-24 ストレス関連障害を含む機能的身体障害の予防および処置 Withdrawn JP2005523334A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37506802P 2002-04-24 2002-04-24
US46428803P 2003-04-18 2003-04-18
PCT/US2003/013247 WO2003090743A1 (en) 2002-04-24 2003-04-24 Prevention and treatment of functional somatic disorders, including stress-related disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009295495A Division JP2010070573A (ja) 2002-04-24 2009-12-25 ストレス関連障害を含む機能的身体障害の予防および処置

Publications (2)

Publication Number Publication Date
JP2005523334A JP2005523334A (ja) 2005-08-04
JP2005523334A5 true JP2005523334A5 (enExample) 2006-06-15

Family

ID=29273017

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003587377A Withdrawn JP2005523334A (ja) 2002-04-24 2003-04-24 ストレス関連障害を含む機能的身体障害の予防および処置
JP2009295495A Pending JP2010070573A (ja) 2002-04-24 2009-12-25 ストレス関連障害を含む機能的身体障害の予防および処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009295495A Pending JP2010070573A (ja) 2002-04-24 2009-12-25 ストレス関連障害を含む機能的身体障害の予防および処置

Country Status (8)

Country Link
US (2) US20030232805A1 (enExample)
EP (1) EP1499309A4 (enExample)
JP (2) JP2005523334A (enExample)
CN (1) CN1662231A (enExample)
AU (1) AU2003225206B2 (enExample)
CA (1) CA2483093A1 (enExample)
MX (1) MXPA04011529A (enExample)
WO (1) WO2003090743A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
TW200402289A (en) * 2002-05-17 2004-02-16 Wyeth Corp Methods of treating gastrointestinary and genitourinary pain disorders
AU2003227519A1 (en) * 2002-05-30 2003-12-19 Head Explorer A/S The use of milnacipran for the treatment of tension-type headache
JP2006504795A (ja) * 2002-10-03 2006-02-09 サイプレス バイオサイエンス， インコーポレイテッド 神経学的障害を処置するための抗うつ剤の投薬量の段階的な漸増ならびに毎日の分割した投薬
US7704527B2 (en) * 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
MXPA05004935A (es) * 2002-11-19 2005-07-22 Lilly Co Eli Tratamiento de desordenes gastrointestinales con duloxetina.
FR2851163B1 (fr) * 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
NZ541733A (en) * 2003-02-14 2009-03-31 Pf Medicament Use of the enantiomer (1S,2R) of milnacipran for the preparation of a medicament
EP1644004A4 (en) * 2003-06-20 2010-10-06 Ronald Aung-Din LOCAL THERAPY FOR THE TREATMENT OF MIGRAINS, MUSCLE CLARIFICATIONS, MUSCLE SPASMS, SPASTICITY AND RELATED CONDITIONS
MXPA06002778A (es) * 2003-09-09 2006-06-14 Pfizer Prod Inc Combinacion de inhibidores de recaptacion de serotonina e inhibidores de recaptacion de norepinefrina.
WO2005025563A1 (en) * 2003-09-12 2005-03-24 Warner-Lambert Company Llc Combination comprising an alpha-2-delta ligand and an ssri and/or snri for treatment of depression and anxiety disorders
EP1894565B1 (en) * 2005-06-10 2013-10-30 Pierre Fabre Médicament S.A. Stabilized milnacipran formulation
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
NZ583193A (en) * 2007-07-23 2012-05-25 Biotie Therapies Inc Treatment of post-traumatic stress disorder with nepicastat
US20100040680A1 (en) * 2008-08-15 2010-02-18 Felix Lai Multiparticulate selective serotonin and norepinephrine reuptake inhibitor formulation
JP2013510176A (ja) 2009-11-06 2013-03-21 ピエール ファーブル メディカモン （１ｓ，２ｒ）−２−（アミノメチル）−ｎ，ｎ−ジエチル−１−フェニルシクロプロパンカルボキサミドの新規結晶形態
FR2978350B1 (fr) 2011-07-28 2013-11-08 Pf Medicament Medicament a base de levomilnacipran pour la rehabilitation fonctionnelle apres accident neurologique aigu
EP3377050A4 (en) 2015-11-17 2019-11-20 The Trustees of Columbia University in the City of New York PHARMACOLOGICAL PROPHYLACTICS AGAINST STRESS-INDUCED AFFECTIVE DISORDERS AND THEIR ASSOCIATED SYMPTOMS
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US11491120B2 (en) 2017-11-09 2022-11-08 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
US11622948B2 (en) 2017-11-09 2023-04-11 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
KR20220008824A (ko) 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법
AU2021206286A1 (en) * 2020-01-10 2024-08-08 Consynance Therapeutics, Inc. Therapeutic combinations of drugs and methods of using them

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2508035A1 (fr) * 1981-06-23 1982-12-24 Fabre Sa Pierre Derives d'aryl-1-aminomethyl-2 cyclopropanes carboxamides (z), leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central
US4535186A (en) * 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
US4761501A (en) * 1983-10-26 1988-08-02 American Home Products Corporation Substituted phenylacetamides
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
AU4542893A (en) * 1992-06-23 1994-01-24 Sepracor, Inc. Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
US5352683A (en) * 1993-03-05 1994-10-04 Virginia Commonwealth University Medical College Of Virginia Method for the treatment of chronic pain
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
US5621142A (en) * 1994-02-22 1997-04-15 Asahi Kasei Kogyo Kabushiki Kaisha Aminoalkylcyclopropane derivatives
ZA958725B (en) * 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
CA2250042A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Treating pain using a synergistic combination of an atypical antipsychotic and a drug used in treatment of pain
PL187926B1 (pl) * 1996-03-25 2004-11-30 Lilly Co Eli Kompozycja farmaceutyczna do leczenia bólu
GB9617990D0 (en) * 1996-08-29 1996-10-09 Scotia Holdings Plc Treatment of pain
US6284794B1 (en) * 1996-11-05 2001-09-04 Head Explorer Aps Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
CA2289190A1 (en) * 1997-05-07 1998-11-12 Algos Pharmaceutical Corporation Composition and method combining an antidepressant with an nmda receptor antagonist, for treating neuropathic pain
UA56257C2 (uk) * 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
WO1999020279A1 (en) * 1997-10-17 1999-04-29 Eli Lilly And Company Potentiation of pharmaceuticals
CA2337507A1 (en) * 1998-07-16 2000-01-27 Massachusetts Institute Of Technology Composition for treatment of stress
AU746887B2 (en) * 1998-09-15 2002-05-02 Eli Lilly And Company Treatment of persistent pain
HK1040908B (en) * 1998-10-27 2005-04-22 Vela Pharmaceuticals Inc. Use of optically pure (r)-tofisopam for treating and preventing anxiety disorders
ES2194536T3 (es) * 1998-11-13 2003-11-16 Lilly Co Eli Combinacion de duloxetina con farmacos antiinflamatorios no esteroideos.
US6323242B1 (en) * 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US6489341B1 (en) * 1999-06-02 2002-12-03 Sepracor Inc. Methods for the treatment of neuroleptic and related disorders using sertindole derivatives
ATE305788T1 (de) * 1999-07-01 2005-10-15 Pharmacia & Upjohn Co Llc (s,s)-reboxetin zur behandlung von inkontinenz
ES2262528T3 (es) * 1999-08-04 2006-12-01 Astellas Pharma Inc. Composiciones medicinales estables para administracion oral que utilizan oxidos de hierro.
AR025111A1 (es) * 1999-08-13 2002-11-06 Janus Pharmaceuticals Inc Metodos y composiciones para tratar trastornos de ansiedad generalizada
AP2002002501A0 (en) * 1999-10-07 2002-06-30 Warner Lambert Co Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
GB2355191A (en) * 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
CA2364211A1 (en) * 2000-12-05 2002-06-05 Phillip Branch Chappell Combination treatment for depression, anxiety and psychosis
MXPA03006003A (es) * 2001-01-02 2005-09-08 Upjohn Co Nuevas combinaciones de farmacos.
US20020147196A1 (en) * 2001-04-05 2002-10-10 Quessy Steven Noel Composition and method for treating neuropathic pain
CA2444053C (en) * 2001-04-19 2008-06-17 Warner-Lambert Company Llc Fused bicyclic or tricyclic amino acids
WO2003068211A1 (en) * 2002-02-12 2003-08-21 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
WO2004045718A2 (en) * 2002-11-20 2004-06-03 Cypress Bioscience, Inc. Treatment of cognitive dysfunctions'

Similar Documents

Publication Publication Date Title
Predictable et al. Side effects of antidepressants: an overview
Nemeroff et al. Duloxetine for the treatment of major depressive disorder
Racagni et al. The pharmacological properties of antidepressants
JP2013544850A5 (enExample)
Bellingham et al. Duloxetine: a review of its pharmacology and use in chronic pain management
JP2009511618A (ja) 中度から重度のむずむず脚症候群（ｒｌｓ）を治療するためのプラミペキソールの使用
US20090306137A1 (en) Treatment for depressive disorders
JP6406713B2 (ja) 低用量薬剤によるうつ病および他の疾患の処置
JP2016210798A5 (enExample)
Christou et al. The efficacy and safety of the naltrexone/bupropion combination for the treatment of obesity: an update
RU2005128548A (ru) Применение (1s,2r) этантиомера милнаципрана для получения лекарственного средства
JP2011522035A5 (enExample)
JP2005539068A5 (enExample)
RU2008112192A (ru) Милнаципран в качестве средства для продолжительного лечения синдрома фибромиалгии
AU2010211491A1 (en) Medical use of 5-benzylaminosalicylic acid derivative or its salt
RU2020125170A (ru) Композиции и способы улучшения биодоступности 5-гидрокситриптофана
JP2015534563A5 (enExample)
JP2012036212A (ja) ムスカリン性受容体ｍ１拮抗剤を使用する精神状態の処置
CN101257907A (zh) 左旋佐匹克隆和抗抑郁剂的组合
ES2625142T3 (es) Usos terapéuticos de 1-[2-(2,4-dimetil-fenilsulfanil)fenil]-piperacina
WO2007047372A3 (en) Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists
JP5553955B2 (ja) 鬱病の処置のための蘇生薬モダフィニルおよび抗鬱薬の組み合わせ
CN1889996A (zh) 氟吡丁和曲马多的组合
JP2007505156A5 (enExample)
WO2004100939B1 (en) Combination of the analeptic modafinil and an antidepressant for the treatment of depression